Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Dr. Vokes on Curative Treatment Approaches in Head and Neck Cancer

December 2nd 2016

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses curative treatment approaches for patients with head and neck cancer.

Dr. Vokes on the Treatment Landscape of Recurrent Head and Neck Cancer

November 23rd 2016

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses the treatment landscape of recurrent head and neck cancer.

Dr. Shlomo Koyfman on Radiation in Recurrent Head and Neck Cancer

November 22nd 2016

Shlomo Koyfman, MD, associate staff, radiation oncology, Cleveland Clinic, discusses radiation therapy in recurrent head and neck cancer.

Vokes on Increasing Impact of Immunotherapy in Head and Neck Cancer

November 18th 2016

As immunotherapy continues to make headway in several different cancer types, these agents are only just arriving to the treatment landscape of head and neck cancer.

Lirilumab/Nivolumab Combo Highly Effective in Head and Neck Cancer

November 13th 2016

The combination of lirilumab and nivolumab resulted in an objective response rate of 24.1% in patients with squamous cell carcinoma of the head and neck.

Dr. Vokes on Nivolumab, Pembrolizumab Approvals in Head and Neck Cancer

November 12th 2016

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses the FDA approvals of the PD-L1 inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda) for the treatment of patients with head and neck cancer.

FDA Approves Nivolumab for Head and Neck Cancer

November 11th 2016

The FDA has approved nivolumab for patients with metastatic or recurrent squamous cell carcinoma of the head and neck following progression on platinum-based therapy.

Dr. Ferris on FDA Approval of Nivolumab in Patients With Head and Neck Cancer

November 11th 2016

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the impact of the FDA approval of nivolumab (Opdivo) for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCN).

Immune-Based Approaches in the Curative Setting of HNSCC

November 7th 2016

Emerging Concepts for Immunotherapy in HNSCC

November 7th 2016

Patient Selection for Pembrolizumab in HNSCC

November 7th 2016

Pembrolizumab and Nivolumab in Recurrent HNSCC

November 7th 2016

Enter PD-1 Inhibitors; A New Paradigm for HNSCC

November 7th 2016

Unmet Needs in Recurrent HNSCC

November 7th 2016

Debates Surrounding Induction Chemotherapy in HNSCC

November 7th 2016

Appropriate Use of Chemotherapy in HNSCC

November 7th 2016

Surgery and Radiotherapy for HNSCC

November 7th 2016

Long-Term Toxicity in HNSCC

November 7th 2016

Goals of Therapy for HNSCC

November 7th 2016

Locoregionally Advanced HNSCC

November 7th 2016